These findings implicate the effect of DJ-1 on NRF2 in cancer development and identify DMF as not only an activator, but also an inhibitor of both NRF2 and DJ-1, which may be useful in exploiting the therapeutic potential of these endogenous antioxidants. This evidence concerns the gene PARK7 and cancer.